US Pharma MarketingThree deaths in CAR-T trials prompt halt by Novartis; Bristol Myers programs also paused
Novartis halts CAR-T trials after three patient deaths from an immune overreaction; Bristol Myers pauses zola-cel enrollment. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug…
Three patients died in Novartis trials of its CD19-directed CAR-T treatment following a dangerous immune system response, and a similar therapy from Bristol Myers Squibb has also been put on hold to review safety issues ...
Source: Endpoints News